BioAge Labs Files Q1 2025 10-Q
Ticker: BIOA · Form: 10-Q · Filed: May 6, 2025 · CIK: 1709941
| Field | Detail |
|---|---|
| Company | Bioage Labs, INC. (BIOA) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
BioAge Labs Q1 10-Q filed. Mentions preferred stock, notes, and incentive plans.
AI Summary
BioAge Labs, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial instruments mentioned include Series D1 Redeemable Convertible Preferred Stock and Convertible Promissory Notes. The filing also references the Wellcome Leap Agreement and the Two Thousand Fifteen Equity Incentive Plan.
Why It Matters
This filing provides investors with an update on BioAge Labs' financial position and operational activities for the first quarter of 2025, including details on their capital structure and incentive plans.
Risk Assessment
Risk Level: medium — The filing details financial instruments like convertible preferred stock and promissory notes, which can introduce financial complexity and risk.
Key Players & Entities
- BioAge Labs, Inc. (company) — Filer
- 20250331 (date) — Period of Report
- 20250506 (date) — Filing Date
- 1445A SOUTH 50TH STREET, RICHMOND, CA 94804 (address) — Business and Mail Address
- 510-806-1445 (phone_number) — Business Phone
- Series D1 Redeemable Convertible Preferred Stock (financial_instrument) — Mentioned financial instrument
- Convertible Promissory Notes (financial_instrument) — Mentioned financial instrument
- Wellcome Leap Agreement (agreement) — Mentioned agreement
- Two Thousand Fifteen Equity Incentive Plan (plan) — Mentioned incentive plan
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20250506.
What is BioAge Labs, Inc.'s primary business address?
The business address is 1445A SOUTH 50TH STREET, RICHMOND, CA 94804.
What type of financial instruments are specifically mentioned in the filing details?
The filing details mention Series D1 Redeemable Convertible Preferred Stock and Convertible Promissory Notes.
Does the filing reference any specific agreements or plans?
Yes, the filing references the Wellcome Leap Agreement and the Two Thousand Fifteen Equity Incentive Plan.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding BioAge Labs, Inc. (BIOA).